Core Viewpoint - Rosen Law Firm is reminding investors who purchased RCI Hospitality Holdings, Inc. securities between December 15, 2021, and September 16, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit on November 20, 2025 [1]. Group 1: Class Action Details - Investors who purchased RCI Hospitality securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that defendants made materially false and misleading statements regarding tax fraud and bribery, which understated the legal risks facing RCI Hospitality [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which indicated a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant stock price drop of 18.2% following the release of disappointing first-quarter results, which included a loss of 69 cents per share compared to a net loss of 15 cents per share in the previous year [3]. - Shareholders who purchased America's Car-Mart, Inc. securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and consistently ranking among the top firms in this area since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of WPP plc American Depositary Shares (ADS) of a class action lawsuit with a lead plaintiff deadline of December 8, 2025, for those who bought shares between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased WPP ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit claims that WPP provided misleading statements about its media arm's capabilities, which led to significant market share loss and investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured over $438 million for investors in 2019 alone and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Company Performance - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated [4]. - The company announced the suspension of its full-year 2025 financial guidance and related assumptions [4]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [4]. Group 2: Legal Actions - Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses for those who purchased Agilon Health securities [2]. - Investors may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2]. - Interested parties can join the prospective class action by submitting a form or contacting the firm directly [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [5]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Brunello Cucinelli S.p.A due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation Details - The investigation is prompted by a report from Morpheus Research, which claims that Brunello Cucinelli misrepresented the status of its Russian business operations, stating that its Russian store locations were shut while allegedly continuing to conduct business in Russia [4]. - Following the publication of this report, Brunello Cucinelli's American Depositary Receipts (ADRs) experienced a significant decline of 17.8% on September 25, 2025 [5]. Group 2: Class Action Information - Shareholders who purchased Brunello Cucinelli securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the prospective class action by submitting a form or contacting the Rosen Law Firm directly for more information [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking among the top firms for securities class action settlements since 2013 [6]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers or sellers of Cepton, Inc. common stock during the specified Class Period from July 29, 2024, to January 6, 2025, due to alleged misleading statements made by the company's defendants [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and individuals wishing to serve as lead plaintiff must act by December 8, 2025 [1][3]. - Investors who bought or sold Cepton, Inc. common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Cepton's defendants made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including securing over $438 million for investors in 2019 alone [4].

Core Points - Rosen Law Firm is reminding investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, of the October 20, 2025, lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 20, 2025 [2] - The lawsuit alleges that PubMatic made false and misleading statements regarding its business operations, which led to investor damages when the truth was revealed [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Legal Proceedings - A class action lawsuit has been filed against MoonLake, alleging that the company misled investors regarding the trial design and efficacy data of SLK prior to the announcement of the trial results [1][2][3]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [3]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy being substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, representing a 90% decrease, which analysts described as a "worst case outcome" [2][6]. Product Comparison - SLK's commercial prospects were heavily reliant on demonstrating efficacy comparable to or superior to BIMZELX, which is already FDA-approved for the same indication [4]. - The lawsuit claims that MoonLake made false statements regarding the advantages of SLK's Nanobody structure over traditional monoclonal antibodies, asserting that it would lead to superior clinical benefits [5]. Investor Communication - Throughout the class period, MoonLake promoted SLK's structural advantages, claiming it could achieve benefits unattainable by monoclonal antibodies and positioned it as a potential "gold standard" treatment [5]. - The lawsuit alleges that these statements were misleading and that the company failed to disclose critical information about SLK's clinical efficacy [5][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quanex Building Products Corporation during the specified Class Period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Quanex securities between December 12, 2024, and September 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lawsuit alleges that Quanex made false and misleading statements regarding its operations and the condition of its equipment, which led to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]